BiotechTube
Paion

Paion

PA8.F
Aachen, Germany· Est.
paion.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PAION AG was a publicly listed German biopharmaceutical company focused on hospital-based sedation, anesthesia, and critical care. Its core achievement was the development and global regulatory approval of remimazolam, a novel, controllable benzodiazepine sedative. The company pursued a hybrid strategy of internal development and strategic in-licensing (e.g., GIAPREZA, XERAVA) but ultimately entered insolvency proceedings in January 2024, leading to the sale of its operating assets to a new entity, PAION Pharma GmbH.

Anesthesia & SedationCritical Care

Technology Platform

Focused development and lifecycle management of ester-based metabolized sedatives (remimazolam) combined with strategic in-licensing of hospital-critical care therapeutics.

Opportunities

The new entity, PAION Pharma GmbH, has the opportunity to leverage a portfolio of approved hospital products with a clean balance sheet.
A focused, lean commercial strategy targeting key European hospital accounts could establish a sustainable niche business.
Continued royalty streams from global partners provide a baseline revenue.

Risk Factors

The new company inherits the same intense competition from low-cost generic standards of care and crowded critical care markets.
Success requires overcoming the commercial execution challenges that led to the predecessor's insolvency.
Future growth is dependent on the performance of external licensing partners in major markets like the U.S.
and China.

Competitive Landscape

Remimazolam competed directly against generic midazolam and propofol, requiring demonstration of superior pharmacokinetics to justify a premium price. In critical care, GIAPREZA and XERAVA faced entrenched competitors in complex, cost-sensitive hospital treatment algorithms, making market penetration a significant challenge.

More companies in Small Molecule Drugs →More companies in Germany →